Review of Pharmacoeconomic Studies in Radionuclide Therapy of Painful Bone Metastases

Voloznev L.V.

IJNMR-S1A9-Lev

Differences in applying radiopharmaceuticals to treat metastatic bone cancer

Krilov V.V., Kochetova T.U., Belozerova M.S., Voloznev L.V.

Okteotid, ¹¹¹in diagnosing and treating medullary thyroid cancer

Reshetov I.V., Mirzoyanc S.G., Shevalgin A.A.

¹⁸⁸Re-Zoledronic acid — new Russian radiopharmaceutical for therapeutic purposes. First clinical trial

Kochetova T.Y., Krilov V.V., Smoliarchuk M.IA., Voloznev L.V., Lynev A.S.

Clinical trial of applying Rezoscan ^99mТс in diagnosing damaged metastatic bone tissue

Znamensky I. A., Servyli E.A., Strabikina D.S., Kondakov A.K., Mosin D.U.

Developmental mechanisms of metastatic damaged skeleton and theraupetic role of N- Bisphosphonates

Voloznev L.V.

Experimental evaluation of functional application of ¹⁸⁸Re-Zoledronic acid

Voloznev L.V., Klementeva O.E., Korsunskiy V. N., Lisenko N.P.

Safety evaluation and dosage of a ¹⁸⁸Re-Zoledronic acid in a clinical trial

Voloznev L.V., Lunev A.S., Klementeva O.E., Korsunskiy V. N.

Labeled by the Zoledronic acid radiopharmaceuticals for metastatic bone cancer patients

Fomin D.K., Lugai O.O., Nazarov A.A.

Preparation and biodistribution of ^99mTc and ¹⁸⁸Re labelled zoledronic acid

Klementyeva O., Malysheva A., Kodina G., Korsunsky V., Rabinovich E., Voloznev L., Krylov V.

Experimental evaluation of Octreotide that has been labeled by Indium-111 for Radionuclide Diagnostics of Tumors with High Expression of Somatostatin Receptors

Grinin M.G., Shimanovki N.L.

New radiopharmaceutical Rezoscan ^99mTc for diagnosing skeletal lesions in prostate cancer patients

Apolihin O.I., Sivkov A.V., Oschepkov V.N., etc.

Potential application of a radiopharmaceutical Okteotide ¹¹¹In in oncological practice

Solodkiu V.A., Ivanova V.V., Panishin G.A., Stavitskiu R.V.